CON Stock Analysis: Concentra Holdings Parent | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 4.401m USD | 12M Return: 55.6% | US20603L1026 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.6M
Qual. Beats: 4
Rev. Trend: 94.6%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Concentra Group Holdings Parent, Inc. (CON) is a U.S. provider of occupational health services organized into three segments: Occupational Health centers, Onsite health clinics, and Other business. Founded in 1979 and headquartered in Addison, Texas, the company delivers a broad service mix spanning workers compensation care, employer and consumer health offerings, employer-sponsored primary care at the workplace, urgent care, injury care, preventive care, drug and alcohol screenings, vaccinations, physical examinations, and clinical testing.
Alongside its physical clinics, Concentra operates several specialized units: Concentra Telemed, a telemedicine platform for work-related injuries and illnesses; Concentra Pharmacy, which distributes repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps employers manage regulated and non-regulated drug and alcohol testing programs. The company is classified within the GICS Health Care Services sub-industry, a sector that typically generates revenue by providing outsourced clinical and administrative services to employers, payers, and patients rather than through traditional hospital or insurance channels. Concentra began trading on the NYSE on July 25, 2024.
- Workers comp claim volume tracks US employment and labor market strength
- Onsite clinic segment expansion drives same-center revenue growth
- Telemedicine adoption and pricing power expand occupational health margins
| Net Income: 198.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.04 > 1.0 |
| NWC/Revenue: 6.06% < 20% (prev 3.00%; Δ 3.06% < -1%) |
| CFO/TA 0.11 > 3% & CFO 335.5m > Net Income 198.7m |
| Net Debt (2.56b) to EBITDA (459.8m): 5.56 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.2m) vs 12m ago 0.0% < -2% |
| Gross Margin: 29.31% > 18% (prev 29.92%; Δ -0.60% > 0.5%) |
| Asset Turnover: 78.18% > 50% (prev 70.60%; Δ 7.58% > 0%) |
| Interest Coverage Ratio: 3.54 > 6 (EBIT TTM 380.0m / Interest Expense TTM 107.3m) |
| A: 0.05 (Total Current Assets 506.5m - Total Current Liabilities 367.9m) / Total Assets 3.01b |
| B: 0.08 (Retained Earnings 244.2m / Total Assets 3.01b) |
| C: 0.13 (EBIT TTM 380.0m / Avg Total Assets 2.93b) |
| D: 0.19 (Book Value of Equity 477.1m / Total Liabilities 2.50b) |
| Altman-Z'' = 1.64 = BB |
| DSRI: 0.97 (Receivables 299.8m/271.8m, Revenue 2.29b/2.01b) |
| GMI: 1.02 (GM 29.92% / 29.31%) |
| AQI: 0.95 (AQ_t 0.58 / AQ_t-1 0.62) |
| SGI: 1.14 (Revenue 2.29b / 2.01b) |
| TATA: -0.05 (NI 198.7m - CFO 335.5m) / TA 3.01b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of September 10, 2026, the stock is trading at USD 34.18 with a total of 593,554 shares traded. Over the past week, the price has changed by +0.86%, over one month by +0.42%, over three months by +31.15% and over the past year by +55.60%.
Current recommended Stop Loss: 31.90 (which is 6.7% or 2.7 ATR below the current price).
Concentra Holdings Parent has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CON.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39.9 | 16.7% |
P/E Trailing = 22.2645
P/E Forward = 17.5747
P/S = 1.9238
P/B = 9.0581
Revenue TTM = 2.29b USD
EBIT TTM = 380.0m USD
EBITDA TTM = 459.8m USD
Long Term Debt = 1.56b USD (from longTermDebt, last quarter)
Short Term Debt = 99.6m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter) + Leases 570.2m
Net Debt = 2.56b USD (calculated: Debt 2.71b - CCE 158.0m)
Enterprise Value = 6.96b USD (4.40b + Debt 2.71b - CCE 158.0m)
Interest Coverage Ratio = 3.54 (Ebit TTM 380.0m / Interest Expense TTM 107.3m)
EV/FCF = 19.89x (Enterprise Value 6.96b / FCF TTM 349.8m)
FCF Yield = 5.03% (FCF TTM 349.8m / Enterprise Value 6.96b)
FCF Margin = 15.29% (FCF TTM 349.8m / Revenue TTM 2.29b)
Net Margin = 8.69% (Net Income TTM 198.7m / Revenue TTM 2.29b)
Gross Margin = 29.31% ((Revenue TTM 2.29b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 31.70% (prev 29.93%)
Tobins Q-Ratio = 2.31 (Enterprise Value 6.96b / Total Assets 3.01b)
Interest Expense / Debt = 3.95% (Interest Expense 107.3m / Debt 2.71b)
Taxrate = 23.15% (61.9m / 267.5m)
NOPAT = 292.1m (EBIT 380.0m * (1 - 23.15%))
Current Ratio = 1.38 (Total Current Assets 506.5m / Total Current Liabilities 367.9m)
Debt / Equity = 5.69 (Debt 2.71b / totalStockholderEquity, last quarter 477.1m)
Debt / EBITDA = 5.56 (Net Debt 2.56b / EBITDA 459.8m)
Debt / FCF = 7.31 (Net Debt 2.56b / FCF TTM 349.8m)
Total Stockholder Equity = 420.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.79% (Net Income 198.7m / Total Assets 3.01b)
RoE = 47.30% (Net Income TTM 198.7m / Total Stockholder Equity 420.1m)
RoCE = 19.18% (EBIT 380.0m / Capital Employed (Equity 420.1m + L.T.Debt 1.56b))
RoIC = 11.11% (NOPAT 292.1m / Invested Capital 2.63b)
WACC = 6.00% (E(4.40b)/V(7.11b) * Re(7.82%) + D(2.71b)/V(7.11b) * Rd(3.95%) * (1-Tc(0.23)))
Discount Rate = 7.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.15 | Cagr: 0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈284.6m ; Y1≈326.3m ; Y5≈480.2m
[DCF] Fair Price = 36.62 (EV 7.23b - Net Debt 2.56b = Equity 4.67b / Shares 127.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 4
Revenue Correlation: 94.62 | Revenue CAGR: 8.49% | SUE: 1.72 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.44 | Chg30d=+4.02% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=1.64 | Chg30d=+7.69% | Revisions=+25% | GrowthEPS=+19.7% | GrowthRev=+8.7%
EPS next Year (2027-12-31): EPS=1.83 | Chg30d=+8.28% | Revisions=+25% | GrowthEPS=+11.6% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +50% (up=3, down=0)